Article Text

PDF
057
NEUROMYELITIS OPTICA IN SOUTH WALES AND THE SOUTH WEST OF ENGLAND
  1. S Luppe1–3,*,
  2. KA Harding1–3,
  3. M Cossburn1–3,
  4. G Ingram1–3,
  5. J Palace1–3,
  6. J Kitley1–3,
  7. MI Leite1–3,
  8. A Jacob1–3,
  9. NP Robertson1–3
  1. 1Cardiff University
  2. 2University of Liverpool
  3. 3University of Oxford

    Abstract

    Objectives To study disease frequency, clinical disease course and relapse rate, in a population-based cohort of patients with NMO and to examine currently employed treatment strategies.

    Methods Patients were identified from seven neurology departments in S Wales and SW England by a multi-source ascertainment strategy. Clinical records were scrutinised and patients interviewed according to a standardized proforma to confirm demographic details including dates of clinical events and therapeutic interventions. Detailed neurological examination including disability assessment was undertaken and patients entered into a structured prospective clinical study.

    Results 36 patients were identified fulfilling established criteria for NMO or NMO spectrum disorders, 31(86%) were anti-AQP4 positive, 3(8%) were non-Caucasian. F : M ratio was 9 : 1, median age at onset 38.1 years (range 4–77), mean disease duration 9 years (SD=9.2), and a mean annual relapse rate 0.84 (SD=0.62). Clinical presentation was heterogeneous: optic neuritis (34%), transverse myelitis (59%), brainstem syndrome (6%). Median delay from onset to EDSS 4 was 7 years. 79% had received long-term immunosuppressive therapy with the use of 10 different therapeutic interventions.

    Conclusion This study provides data on the disease course, relapse rate and disability accrual in NMO in a cohort of 36 patients. Our data suggest a high variability of treatment regimes. After analysis and consultation with other UK groups we propose a unified treatment algorithm for management of patients with this disorder.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.